{"entity":{"id":"biomed-valley-discoveries","kind":"company","name":"Biomed Valley Discoveries","aka":["BioMed Valley Discoveries, Inc.","Biomed Valley Discoveries Inc.","BVD"],"tldr":"Biomed Valley Discoveries is a Kansas City company owned through the Stowers Institute for Medical Research. Its main medicine, ulixertinib, blocks ERK, the last step of a growth signalling chain that is switched on in many cancers and in histiocytosis.","summary":"Biomed Valley Discoveries, Inc. (BVD) describes itself as a clinical-stage biotechnology company based in Kansas City, Missouri, wholly owned by a supporting organisation of the non-profit Stowers Institute for Medical Research and funded through American Century Investments. Its lead programme is ulixertinib (BVD-523), which the company calls a highly selective ERK1/2 inhibitor, in phase 2 development; its website lists histiocytosis (NCT06411821), adult and paediatric low- and high-grade glioma (NCT05804227) and myelofibrosis with ruxolitinib (NCT06773195) as its priorities, and says a paediatric low-grade glioma trial is planned for 2026. It also lists TEM8/ANTXR1 antibodies for antibody-drug conjugates (preclinical) and a Clostridium novyi-NT bacterial programme whose phase 1 is complete. The FDA designated ulixertinib an orphan drug for BRAF-mutant melanoma in 2013, and on 27 August 2026 granted the company a designation for malignant glioma for a product it describes as a reversible ATP-competitive ERK1/2 inhibitor.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://biomed-valley.com/"},{"label":"Ulixertinib programme page","url":"https://biomed-valley.com/ulixertinib/"},{"label":"FDA orphan designation, malignant glioma, 27 August 2026","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1173826"},{"label":"FDA orphan designation of ulixertinib, melanoma, 2013","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=398213"}],"tags":[],"related":[],"cancers":["glioblastoma","erdheim-chester-disease"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["mapk1","mapk3"],"drugs":["ulixertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The 2026 FDA record does not name the product; ulixertinib is the only ERK1/2 inhibitor on the company's pipeline. The window-of-opportunity glioma trial NCT05804227 is sponsored by MD Anderson Cancer Center and the histiocytosis trial NCT06411821 by Memorial Sloan Kettering. Read on 4 November 2026."],"hq":"Kansas City, MO","country":"US","companyType":"biotech","website":"https://biomed-valley.com/","investors":[],"funding":[]},"route":"/companies/biomed-valley-discoveries/","neighbours":{"cancer":[{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"mapk1","kind":"target","name":"MAPK1","route":"/targets/mapk1/"},{"id":"mapk3","kind":"target","name":"MAPK3","route":"/targets/mapk3/"}],"drug":[{"id":"ulixertinib","kind":"drug","name":"Ulixertinib","route":"/drugs/ulixertinib/"}]}}